UTIPRO® PLUS

1

A new publication confirms the role of xyloglucan as a mucosa protector in the management of urinary tract infections

Esposito E et al. Effect of xyloglucan against Escherichia coli extraintestinal urinary tract infection: an in vivo study. Microb Physiol. Published online: Oct 16, 2020. DOI: 10.1159/000510874

Urinary tract infections account for the third most common type of infectious pathology after respiratory and gastrointestinal processes. The agent responsible for such urinary tract infections is in most cases the bacterium Escherichia coli that migrates from the intestine and invades the urinary tract. In a recent publication in Microbial Physiology, Dr Emanuela Esposito, of the University of Messina, under the direction of Professor Salvatore Cuzzocrea, has seen in a study conducted in rats infected with E coli as their intestinal and urinary bacterial load is significantly reduced when they are previously treated with xyloglucan alone or with xyloglucan combined with gelose. Similarly, histological lesions in the intestinal and urinary wall resulting from infection are reduced. It is thus confirmed that these polymeric substances create a physical barrier that reduces intestinal reservoirs of pathogenic bacteria supporting their beneficial role in the treatment and prevention of urinary tract infections. The marketed products containing these substances in their composition can thus see their totally innovative mode of action fully explained.

Read more

Urinary tract infections in the elderly: a review of disease characteristics and current treatment options

Rodriguez-Mañas L. Urinary tract infections in the elderly: a review of disease characteristics and current treatment options. Drugs in Context 2020; 9: 2020-4-13. DOI: 10.7573/dic.2020-4-13. Free PMC article.

Despite the high prevalence of UTIs in the elderly, treatment options are limited. Although the medical community may agree in principle about the need for rational antibiotic usage, the absence of effective alternatives to treat UTIs can be a genuine barrier to change. Elderly patients are not only more prone to UTIs but are also more likely to have comorbidities and require multiple medications. The option to use a device that acts in a physical manner (barrier effect) without pharmacological properties, and with potential to reduce antimicrobial use, has obvious appeal in this patient population.

Read more

Xyloglucan, hibiscus and propolis to reduce symptoms and antibiotics use in recurrent UTIs: a prospective study.

Cai T et al. Future Microbiol. 2019 Aug;14:1013-1021.

The results of a new prospective observational clinical trial carried out in women with recurrent Urinary Tract Infections (rUTIs) have demonstrated that the use of a medical device containing xyloglucan, hibiscus and propolis reduces both recurrences and the use of antibiotics. Moreover, the study showed remarkable results since almost 84% of patients reported a notable clinical improvement of QoL with a statistically significant difference compared with baseline after 6 months from the beginning of the treatment. It is also concluded that although antibiotics are still considered the pillar for the management of UTIs, the spread of multidrug-resistant microorganisms is worryingly rising and requires thorough monitoring and novel preventive approaches. This is an independent study, coordinated by Dr. Tommaso Cai, member of the board of EAU Guidelines and part of several other Italian and international institutions that, since a long time, are fully committed in the rationalisation of the use of antibiotics.

Read more

Let's meet in..

2021, Mar 01

euroPLX 75 Lisbon

Read more